Evidence map›Paper›PMID 33067416›Full record

ArticleCell death & disease2020

Correction: P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma.

Caterina Costa, Paola Indovina, Eliseo Mattioli, Iris Maria Forte, Carmelina Antonella Iannuzzi, Luca Luzzi, Cristiana Bellan, Simona De Summa, Enrico Bucci, Domenico Di Marzo and 4 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.Journal of experimental & clinical cancer research : CR · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Caterina CostaCell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, I-80131, Napoli, Italy.ORCID http://orcid.org/0000-0003-0909-7366
Paola IndovinaSbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, 19122, USA.
Eliseo MattioliHistopathological Unit, IRCCS-Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy.
Iris Maria ForteCell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, I-80131, Napoli, Italy.
Carmelina Antonella IannuzziCell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, I-80131, Napoli, Italy.
Luca LuzziThoracic Surgery Unit, Department of Medicine, Surgery and Neuro Sciences, Diagnostic Imaging, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Cristiana BellanDepartment of Medical Biotechnologies, University of Siena, Siena, 53100, Italy.
Simona De SummaMolecular Diagnostics and Pharmacogenetics Unit-IRCCS-Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy.ORCID http://orcid.org/0000-0001-9607-3754
Enrico BucciSbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, 19122, USA.ORCID http://orcid.org/0000-0002-3317-8003
Domenico Di MarzoSbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, 19122, USA.
Marisa De FeoDepartment of Cardiothoracic Sciences, Università degli Studi della Campania 'L. Vanvitelli' c/o Monaldi Hospital, Via L. Bianchi, 80131, Napoli, Italy.
Luciano MuttiSbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, 19122, USA.ORCID http://orcid.org/0000-0002-1578-2637
Francesca PentimalliCell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, I-80131, Napoli, Italy. f.pentimalli@istitutotumori.na.it.ORCID http://orcid.org/0000-0003-4740-6801
Antonio GiordanoSbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, 19122, USA.ORCID http://orcid.org/0000-0002-5959-016X
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITTemple University · USUniversity of Siena · ITIstituto Tumori Bari · ITInstitute for High Performance Computing and Networking · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Author Francesca Pentimalli was incorrectly associated with Histopathological Unit, IRCCS-Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124 Bari, Italy. The author's actual affiliation is Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, I-80131 Napoli, Italy.

Identifiers

PMID33067416
PMCPMC7567790
OpenAlexW3092977018

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.